Viva Biotech HoldingsFRA:VB0 +2.59%47 Quick Ratio is 1.27 as of Dec. 2025, which is 37% below its 10-year median of 2.03. GuruFocus rates FRA:VB0 with a GF Score™ of 47/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,412 Biotechnology companies, Viva Biotech Holdings ranks worse than 76.63% on this metric.
Viva Biotech Holdings has a quick ratio of 1.27. It generally indicates good short-term financial strength.
The historical rank and industry rank for Viva Biotech Holdings's Quick Ratio or its related term are showing as below:
FRA:VB0'
s Quick Ratio Range Over the Past 10 Years
Min: 0.6 Med: 2.03 Max: 14.88
Current: 1.27
During the past 10 years, Viva Biotech Holdings's highest Quick Ratio was 14.88. The lowest was 0.60. And the median was 2.03.
FRA:VB0's Quick Ratio is ranked worse than 76.63% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:VB0: 1.27
Viva Biotech Holdings (FRA:VB0) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Viva Biotech Holdings Quick Ratio Related Terms
Viva Biotech Holdings Quick Ratio Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Viva Biotech Holdings's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (FRA:VB0) has a Quick Ratio of 1.27 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Viva Biotech Holdings and its competitors. This is 37% below median its historical median of 2.03. Over the past decade, Viva Biotech Holdings' Quick Ratio has ranged from 0.60 to 14.88. According to the industry distribution chart, Viva Biotech Holdings ranks #1082 out of 1412 companies in the Biotechnology industry, placing it in the top 76.6%.
Is Viva Biotech Holdings' Quick Ratio too high?
Viva Biotech Holdings' current Quick Ratio of 1.27 is 37% below median its 10-year median of 2.03. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 14.88. The Biotechnology industry median Quick Ratio is 3.60. Viva Biotech Holdings' value of 1.27 is 64.7% below this industry median. Based on the distribution chart, Viva Biotech Holdings ranks #1082 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Viva Biotech Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #1082 out of 1412 companies for Quick Ratio. This places Viva Biotech Holdings in the lower half of its industry. The industry median Quick Ratio is 3.60. Viva Biotech Holdings' value of 1.27 is 64.7% below this benchmark. Historically, Viva Biotech Holdings' own Quick Ratio has ranged from 0.60 to 14.88 over the past decade. While the company's 10-year median is 2.03 vs. the industry median of 3.60, Viva Biotech Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viva Biotech Holdings's current Quick Ratio of 1.27 is 64.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Viva Biotech Holdings and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viva Biotech Holdings's current Quick Ratio is 1.27, which is 37% below median its own 10-year median of 2.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.12 — trading 48.8% above its estimated fair value. The current Quick Ratio is 1.27, which is 37% below median its 10-year median of 2.03 and 64.7% below the Biotechnology industry median of 3.60. Viva Biotech Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Quick Ratio is 1.27 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.12 is trading 48.8% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
Quick Ratio: 1.27 (37% below median its 10-year median of 2.03)
GF Value™: €0.08 vs. price of €0.12 (48.8% above fair value)
Industry Position: 64.7% below the Biotechnology median (#1082 of 1412)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
47GF Score
Get the complete analysis for FRA:VB0
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
